225 related articles for article (PubMed ID: 33396205)
1. Pan-Cancer Molecular Patterns and Biological Implications Associated with a Tumor-Specific Molecular Signature.
Rocha D; García IA; González Montoro A; Llera A; Prato L; Girotti MR; Soria G; Fernández EA
Cells; 2020 Dec; 10(1):. PubMed ID: 33396205
[TBL] [Abstract][Full Text] [Related]
2. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
3. Pan-cancer molecular analysis of the RB tumor suppressor pathway.
Knudsen ES; Nambiar R; Rosario SR; Smiraglia DJ; Goodrich DW; Witkiewicz AK
Commun Biol; 2020 Apr; 3(1):158. PubMed ID: 32242058
[TBL] [Abstract][Full Text] [Related]
4. LinkedOmics: analyzing multi-omics data within and across 32 cancer types.
Vasaikar SV; Straub P; Wang J; Zhang B
Nucleic Acids Res; 2018 Jan; 46(D1):D956-D963. PubMed ID: 29136207
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
6. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
[TBL] [Abstract][Full Text] [Related]
7. Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.
Zerdes I; Sifakis EG; Matikas A; Chrétien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
Mol Oncol; 2020 May; 14(5):951-963. PubMed ID: 32115850
[TBL] [Abstract][Full Text] [Related]
8. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
[TBL] [Abstract][Full Text] [Related]
9. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells.
Geisinger JM; Stearns T
Nucleic Acids Res; 2020 Sep; 48(16):9067-9081. PubMed ID: 32687165
[TBL] [Abstract][Full Text] [Related]
11. Enhanced immortalization, HUWE1 mutations and other biological drivers of breast invasive carcinoma in Black/African American patients.
Andey T; Attah MM; Akwaaba-Reynolds NA; Cheema S; Parvin-Nejad S; Acquaah-Mensah GK
Gene; 2020 Dec; 763S():100030. PubMed ID: 34493366
[TBL] [Abstract][Full Text] [Related]
12. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
McMullin RP; Wittner BS; Yang C; Denton-Schneider BR; Hicks D; Singavarapu R; Moulis S; Lee J; Akbari MR; Narod SA; Aldape KD; Steeg PS; Ramaswamy S; Sgroi DC
Breast Cancer Res; 2014 Mar; 16(2):R25. PubMed ID: 24625110
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A; Padellan M; Marchenko N
Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
[TBL] [Abstract][Full Text] [Related]
14. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
[TBL] [Abstract][Full Text] [Related]
15. The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer.
Xiang T; Li L; Yin X; Yuan C; Tan C; Su X; Xiong L; Putti TC; Oberst M; Kelly K; Ren G; Tao Q
PLoS One; 2012; 7(1):e29783. PubMed ID: 22279545
[TBL] [Abstract][Full Text] [Related]
16. Research-based PAM50 signature and long-term breast cancer survival.
Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
[TBL] [Abstract][Full Text] [Related]
17. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
[TBL] [Abstract][Full Text] [Related]
18. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
19.
Fang Z; Wang Y; Wang Z; Xu M; Ren S; Yang D; Hong M; Xie W
Cancer Res; 2020 Oct; 80(20):4399-4413. PubMed ID: 32826278
[TBL] [Abstract][Full Text] [Related]
20. Identifying cancer subtypes based on embryonic and hematopoietic stem cell signatures in pan-cancer.
Lei J; Luo J; Liu Q; Wang X
Cell Oncol (Dordr); 2024 Apr; 47(2):587-605. PubMed ID: 37821797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]